Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches

Executive Summary

CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.

Advertisement

Related Content

Teva: No Reason To "Panic" When It Comes To Ajovy Access
Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal
Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor
Lilly Moves Into Migraine Race With CHMP Okay
Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?
Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel